Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients.

The article presents information on a study conducted to evaluate the immunogenicity as well as safety of the influenza A H1N1/2009 vaccine in children aged below 9 years old with autoimmune rheumatic diseases (ARD). The study was conducted on thirty-eight ARD patients as well as 11 healthy children. The study concluded that the vaccine is appropriate for the age group.